Current vice president and Democratic Party presidential nominee Kamala Harris has proposed sweeping changes designed to ...

While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.

Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy ...

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.

A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s ...

Novo Nordisk says Massachusetts plays a key role in its bid to expand beyond its historic focus as a diabetes and obesity ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 ...

The general mood among these heavyweight investors is divided, with 45% leaning bullish and 50% bearish. Among these notable ...

“Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic ...